Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
10 Feb 23
10-Q
2022 Q3
Quarterly report
25 Oct 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
Current reports
8-K
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
11 Apr 24
8-K
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
9 Apr 24
8-K
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
19 Mar 24
8-K
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
14 Mar 24
8-K
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
9 Nov 23
8-K
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
10 Aug 23
8-K
Entry into a Material Definitive Agreement
23 Jun 23
8-K
Financial Statements and Supplementary Data
23 Jun 23
8-K
Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
11 May 23
8-K/A
Regulation FD Disclosure
21 Mar 23
Registration and prospectus
S-3
Shelf registration
18 Apr 24
D
$90.00 mm in equity / options / securities to be acquired, sold $90.00 mm, 20 investors
3 Apr 24
S-8
Registration of securities for employees
14 Mar 24
424B5
Prospectus supplement for primary offering
6 Jul 23
S-3
Shelf registration
23 Jun 23
S-8
Registration of securities for employees
1 Mar 23
425
Business combination disclosure
22 Feb 23
425
Business combination disclosure
13 Feb 23
424B3
Prospectus supplement
23 Jan 23
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
19 Oct 22
DEFM14A
Proxy related to merger
7 Oct 22
PREM14A
Preliminary proxy related to merger
23 Sep 22
DEFA14A
Additional proxy soliciting materials
7 Sep 22
DEFA14A
Additional proxy soliciting materials
22 Apr 22
Other
EFFECT
Notice of effectiveness
5 Jul 23
CORRESP
Correspondence with SEC
29 Jun 23
UPLOAD
Letter from SEC
29 Jun 23
EFFECT
Notice of effectiveness
24 Jan 23
CORRESP
Correspondence with SEC
19 Jan 23
CORRESP
Correspondence with SEC
6 Jan 23
UPLOAD
Letter from SEC
29 Dec 22
CORRESP
Correspondence with SEC
19 Dec 22
UPLOAD
Letter from SEC
7 Dec 22
EFFECT
Notice of effectiveness
9 Apr 21
Ownership
SC 13D/A
5AM Ventures VI, L.P.
15 Apr 24
4
Anish Patel
15 Apr 24
4
Joseph P Lyssikatos
15 Apr 24
4
Samuel Kintz
15 Apr 24
4
Benjamin Hohl
15 Apr 24
4
Richard A. Heyman
15 Apr 24
4
Helen Louise Collins
15 Apr 24
4
Rahul D. Ballal
12 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
144
Notice of proposed sale of securities
11 Apr 24